Kamada (NASDAQ:KMDA - Get Free Report) is set to release its earnings data before the market opens on Wednesday, May 8th. Analysts expect Kamada to post earnings of $0.06 per share for the quarter. Kamada has set its FY 2024 guidance at EPS.Individual interested in registering for the company's earnings conference call can do so using this link.
Kamada (NASDAQ:KMDA - Get Free Report) last issued its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.04. The company had revenue of $36.43 million for the quarter, compared to the consensus estimate of $37.71 million. Kamada had a return on equity of 5.66% and a net margin of 5.81%. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Kamada Stock Performance
Shares of KMDA traded up $0.19 during midday trading on Thursday, hitting $5.56. The company had a trading volume of 38,254 shares, compared to its average volume of 22,556. Kamada has a 1 year low of $4.08 and a 1 year high of $6.53. The firm has a market capitalization of $319.59 million, a P/E ratio of 37.07 and a beta of 1.05. The company's 50-day simple moving average is $5.62 and its 200-day simple moving average is $5.47.
Analyst Ratings Changes
KMDA has been the subject of several analyst reports. StockNews.com upgraded shares of Kamada from a "hold" rating to a "buy" rating in a report on Thursday, January 4th. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Kamada in a research note on Thursday, March 7th.
View Our Latest Research Report on KMDA
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Further Reading
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
